Diagnostic Performance and Kinetics of Hepatitis E Viral RNA and IgM Antibody Test Positivity in a Genotype 1 Outbreak in South Sudan - Takeaways - MDSpire

Diagnostic Performance and Kinetics of Hepatitis E Viral RNA and IgM Antibody Test Positivity in a Genotype 1 Outbreak in South Sudan

  • By

  • Aybüke Koyuncu

  • Robin C Nesbitt

  • Catia Alvarez

  • Kinya Vincent Asilaza

  • Joseph Wamala

  • Melat Haile

  • Etienne Gignoux

  • Manuel Albela

  • Emily S Gurley

  • Frederick Beden Loro

  • Duol Biem

  • Monica Rull

  • John Rumunu

  • Iza Ciglenecki

  • Isabella Eckerle

  • Andrew S Azman

  • August 14, 2025

  • 0 min

Share

  • 1

    The study evaluated the performance of PCR, IgM ELISA, and RDT during a hepatitis E outbreak in South Sudan from March to December 2022.

  • 2

    Test sensitivity for PCR decreased over time from jaundice onset, with 73% sensitivity within 30 days compared to 95% for ELISA.

  • 3

    The Assure IgM RDT demonstrated higher sensitivity than PCR and similar specificity to IgM ELISA, supporting its use in outbreak surveillance.

  • 4

    Median time from jaundice onset to a negative PCR test was 19 days, while it was 113 days for ELISA, indicating differences in test dynamics.

  • 5

    The study highlights the need for improved diagnostic capabilities in low-resource settings to enhance hepatitis E outbreak responses.

Original Source(s)

Diagnostic Performance and Kinetics of Hepatitis E Viral RNA and IgM Antibody Test Positivity in a Genotype 1 Outbreak in South Sudan

  • by Aybüke Koyuncu, Robin C Nesbitt, Catia Alvarez, Kinya Vincent Asilaza, Joseph Wamala, Melat Haile, Etienne Gignoux, Manuel Albela, Emily S Gurley, Frederick Beden Loro, Duol Biem, Monica Rull, John Rumunu, Iza Ciglenecki, Isabella Eckerle, Andrew S Azman

  • August 14, 2025

Related Content

The hantavirus is a wake-up call. Will the Trump administration answer it?

8 former CDC directors: Reform PEPFAR, don’t dismantle it

Shorter TB Regimens Advance Care

Review highlights shorter tuberculosis regimens while warning that rising bedaquiline resistance may threaten future progress.